tetano
Editor, Senior Moderator
iScience
. 2024 Aug 30;27(9):110839.
doi: 10.1016/j.isci.2024.110839. eCollection 2024 Sep 20. Characterization model of the post COVID-19 condition based on immunological, biochemical, and cytokine markers
Bárbara Oliván-Blázquez[SUP] 1 2 3 [/SUP], Marta Bona-Otal[SUP] 4 [/SUP], Fátima Méndez-López[SUP] 2 3 [/SUP], David Lerma-Irureta[SUP] 2 [/SUP], Paula García-Izuel[SUP] 5 [/SUP], Jesús Ibáñez-Ruiz[SUP] 6 [/SUP], Alberto Montolío[SUP] 6 [/SUP], María Ruiz-Herreros[SUP] 7 [/SUP], Javier Godino[SUP] 8 [/SUP], Beatriz Jimeno-Beltran[SUP] 8 [/SUP], María Del Mar Encabo-Berzosa[SUP] 9 [/SUP], Izaskun Arenaz[SUP] 9 [/SUP], Ana Medel-Martínez[SUP] 10 [/SUP], Verónica Casado-Vicente[SUP] 11 [/SUP], Mayte Coiras[SUP] 12 [/SUP], Carlos Tellería-Orriols[SUP] 6 [/SUP], Jon Schoorlemmer[SUP] 13 [/SUP], Rosa Magallón-Botaya[SUP] 2 3 5 [/SUP]
Affiliations
Post-coronavirus disease condition (PCC) continues to affect many people globally, yet there remains a lack of diagnostic biomarkers to distinguish PCC from those recovered from acute COVID-19. This study compared biomarkers between two age- and gender-matched groups: PCC individuals and those recovered within three months of acute COVID-19 in 2020 (n = 85 each). Biomarkers were assessed 12-24 months after initial diagnosis, examining biochemical profiles, blood cell counts, coagulation status, antibody serology, lymphocyte populations, and cytokine levels. PCC individuals exhibited significant alterations in 49 of 167 markers, including K+ levels, αGAD antibodies, antithrombin III, insulin-like growth factor-binding protein 3 (IGFBP3), and interleukin-10 (IL-10). A panel of αGAD, IL-10, potassium levels, and CD16[SUP]bright[/SUP]CD56[SUP]-[/SUP] cell presence distinguished PCC individuals from recovered patients with >88% accuracy and <92% precision.
Keywords: Biochemistry; Immunology; Virology.
. 2024 Aug 30;27(9):110839.
doi: 10.1016/j.isci.2024.110839. eCollection 2024 Sep 20. Characterization model of the post COVID-19 condition based on immunological, biochemical, and cytokine markers
Bárbara Oliván-Blázquez[SUP] 1 2 3 [/SUP], Marta Bona-Otal[SUP] 4 [/SUP], Fátima Méndez-López[SUP] 2 3 [/SUP], David Lerma-Irureta[SUP] 2 [/SUP], Paula García-Izuel[SUP] 5 [/SUP], Jesús Ibáñez-Ruiz[SUP] 6 [/SUP], Alberto Montolío[SUP] 6 [/SUP], María Ruiz-Herreros[SUP] 7 [/SUP], Javier Godino[SUP] 8 [/SUP], Beatriz Jimeno-Beltran[SUP] 8 [/SUP], María Del Mar Encabo-Berzosa[SUP] 9 [/SUP], Izaskun Arenaz[SUP] 9 [/SUP], Ana Medel-Martínez[SUP] 10 [/SUP], Verónica Casado-Vicente[SUP] 11 [/SUP], Mayte Coiras[SUP] 12 [/SUP], Carlos Tellería-Orriols[SUP] 6 [/SUP], Jon Schoorlemmer[SUP] 13 [/SUP], Rosa Magallón-Botaya[SUP] 2 3 5 [/SUP]
Affiliations
- PMID: 39318534
- PMCID: PMC11420445
- DOI: 10.1016/j.isci.2024.110839
Post-coronavirus disease condition (PCC) continues to affect many people globally, yet there remains a lack of diagnostic biomarkers to distinguish PCC from those recovered from acute COVID-19. This study compared biomarkers between two age- and gender-matched groups: PCC individuals and those recovered within three months of acute COVID-19 in 2020 (n = 85 each). Biomarkers were assessed 12-24 months after initial diagnosis, examining biochemical profiles, blood cell counts, coagulation status, antibody serology, lymphocyte populations, and cytokine levels. PCC individuals exhibited significant alterations in 49 of 167 markers, including K+ levels, αGAD antibodies, antithrombin III, insulin-like growth factor-binding protein 3 (IGFBP3), and interleukin-10 (IL-10). A panel of αGAD, IL-10, potassium levels, and CD16[SUP]bright[/SUP]CD56[SUP]-[/SUP] cell presence distinguished PCC individuals from recovered patients with >88% accuracy and <92% precision.
Keywords: Biochemistry; Immunology; Virology.